M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Sponsor: M.D. Anderson Cancer Center
Terminated
Due to the fact that the sponsor decided not to move forward with the development of M7824
Other terminated trials from M.D. Anderson Cancer Center
Other Anatomic Stage IV Breast Cancer AJCC v8 trials with similar outcome
A PHASE1 clinical study on Anatomic Stage IV Breast Cancer AJCC v8 and Metastatic Triple-Negative Breast Carcinoma, this trial is terminated or withdrawn. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Feb 2021 — Sep 2022 [monthly]
Recruiting PHASE1
▶ Show 9 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jan 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Sep 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Jun 2019 — Sep 2019 [monthly]
Recruiting PHASE1
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE1
-
Nov 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE1
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE1
First recorded
May 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .